On May 28, 2021, the U.S. Department of Health and Human Services (HHS) filed a motion urging a District Court to dismiss the Pharmaceutical Research & Manufacturers of America’s (PhRMA) challenge to a federal rule enabling state importation from Canada. The filing signaled the Biden administration’s commitment to defend the rule, which was published in October 2020 under the previous administration. HHS argued that PhRMA lacked standing to pursue the suit because manufacturers have not been harmed by […]
https://www.nashp.org/wp-content/uploads/2021/05/rx-slideshow-5-year-anniversary-2021-1.jpg6411141Melanie Felicianohttps://www.nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngMelanie Feliciano2021-05-18 09:43:422021-05-18 16:23:57Celebrating Five Years of State Action to Lower Drug Prices
In addition to providing critical funding for state COVID-19 response efforts, the American Rescue Plan requires drug manufacturers to pay more in Medicaid rebates for drugs with large price increases. This change, effective in 2024, has the potential to generate significant federal and state savings.
https://www.nashp.org/wp-content/uploads/2019/01/rx-bill-calculator-shutterstock_10_15_2018.jpg37445616Melanie Felicianohttps://www.nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngMelanie Feliciano2021-03-22 19:31:162021-03-23 15:42:53Manufacturers to Pay Higher Rebates for Drugs with Large Price Increases under the American Rescue Plan
https://www.nashp.org/wp-content/uploads/2019/06/NASHP-Logo.png00NASHP Staffhttps://www.nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngNASHP Staff2021-03-15 22:00:532021-03-16 18:35:12Comparison of State Prescription Drug Affordability Board Legislation
Drug makers claim high prices are necessary to support new drug development and innovation, but research shows that public investment in drug research and development combined with large industry profits leaves manufacturers room to lower prices while continuing to innovate.
Three states have proposed legislation, based on National Academy for State Health Policy’s model law, that penalizes drug manufacturers for hiking prescription drug prices without new clinical evidence to justify the increase.
https://www.nashp.org/wp-content/uploads/2019/01/rx-bill-calculator-shutterstock_10_15_2018.jpg37445616Melanie Felicianohttps://www.nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngMelanie Feliciano2021-03-01 21:22:272021-03-02 16:54:24Adding Teeth to Transparency: States Take Stronger Steps Against Drug Price Hikes
https://www.nashp.org/wp-content/uploads/2019/01/rx-bill-calculator-shutterstock_10_15_2018.jpg37445616NASHP Staffhttps://www.nashp.org/wp-content/uploads/2019/06/NASHP-Logo.pngNASHP Staff2021-02-12 21:51:562021-02-16 15:55:33Comparison of State Prescription Drug Affordability Review Initiatives
Portland, Maine Office:
2 Monument Square, Suite 910
Portland, Maine 04101